Clinical trial · Observational
Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia
Population Based Pharmacokinetic and Pharmacodynamic Dosage Model for Cytarabine, Daunorubicin and Etoposide for Acute Myeloid Leukemia
NCT00969891CI-TRIAL-00005399completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PK-PD analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AML patients in induction treatment
- interventionNames
- Other: PK-PD analysis
Primary outcomes (1)
- measure
- significant covariates from the PK study
- timeFrame
- after complete analysis of data
Secondary outcomes (1)
- measure
- Amount of the three drugs in patient plasma samples
- timeFrame
- within 3 months of sampling
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adult men and women with newly diagnosed acute myeloid leukemia Exclusion Criteria: * under age 18 years
References
Publications (0)
Data not yet available
No reference posted for this study.